| Literature DB >> 33101732 |
Oswin Mwemezi1, Paschal Ruggajo1,2, Jonathan Mngumi2, Francis F Furia1,2.
Abstract
BACKGROUND: HIV-associated renal dysfunction is common among infected patients; the growing burden of this condition may be partly accounted for by improved survival attributed to sustained viral suppression with antiretroviral therapies (ART). Some ART regimens are nephrotoxic and may potentially contribute to renal dysfunction observed in these patients. This study aimed at investigating the prevalence of renal dysfunction among people living with HIV (PLHIV) on ART attending the care and treatment clinic (CTC).Entities:
Year: 2020 PMID: 33101732 PMCID: PMC7568141 DOI: 10.1155/2020/8378947
Source DB: PubMed Journal: Int J Nephrol
Demographic and clinical characteristics of HIV patients on antiretroviral therapy at Muhimbili National Hospital (N = 287).
| Characteristics |
| % |
|---|---|---|
|
| ||
| Female | 207 | 72.1 |
|
| ||
| No formal education | 5 | 1.7 |
| Lower education level | 249 | 86.8 |
| Higher education level | 33 | 11.5 |
|
| ||
| Single | 71 | 24.7 |
| Married/cohabiting | 129 | 45.0 |
| Divorced | 87 | 30.3 |
|
| ||
| Tenofovir-based ART regimens | 249 | 86.8 |
| Non-tenofovir-based ART regimens | 38 | 13.2 |
|
| 46.51 ± 10.8 | |
|
| 516 | |
| Median | 464 | |
| Range | 6–1839 | |
|
| 170284 | |
| Median | 50 | |
| Range | 20-39237898 | |
|
| 71 | 24.7 |
| Systolic blood pressure (mean ± SD) | 122 ± 21 | |
| Diastolic blood pressure (mean ± SD) | 78 ± 13 | |
|
| 12 | 4.18 |
| Random blood glucose (mean ± SD) | 5.8 ± 2.5 | |
| Median | 5.3 | |
| Range | 2–23 | |
|
| 42 ± 52.5 | |
| Median | 20 | |
| Range | 2–300 | |
|
| 97.5 ± 24 | |
| Median | 101 | |
| Range | 6–154 |
Factors predictive of renal dysfunction among HIV patients on antiretroviral therapy at Muhimbili National Hospital (N = 287).
| Characteristics | Renal dysfunction, | No renal dysfunction, | Total ( | Univariate OR, 95% CI, | Multivariate OR, 95% CI, |
|---|---|---|---|---|---|
|
| |||||
| Less than or equal to 60 years | 62 (23.4) | 203 (76.6) | 263 | Reference | |
| More than 60 years | 9 (40.9) | 13 (59.1) | 24 |
|
|
|
| |||||
| Male | 23 (28.8) | 57 (71.2) | 80 | Reference | |
| Female | 48 (23.2) | 159 (76.8) | 207 | 0.7, (0.4–1.3), 0.32 | 0.95, (0.5–1.8) 0.9 |
|
| |||||
| Non-tenofovir-based | 13 (34.2) | 25 (65.8) | 38 | Reference | |
| Tenofovir-based | 58 (23.3) | 191 (76.7) | 249 | 0.6, (0.3–1.2), 0.15 | 0.6, (0.3–1.35) 0.23 |
|
| |||||
| Less than 350 cells/mm3 | 27 (31.4) | 59 (68.6) | 86 | 1.6, (0.9–2.8), 0.09 | 1.25, (0.67–2.3) 0.5 |
| 350 cells/mm3 and above | 44 (21.9) | 157 (78.1) | 201 | Reference | |
|
| |||||
| Less than 1000 cp/ml | 59 (23) | 198 (77) | 257 | Reference | |
| 1000 cp/ml or more | 12 (40) | 18 (60) | 30 |
|
|
|
| |||||
| Normal BP | 52 (24.0) | 165 (76) | 2017 | Reference | |
| Hypertensive | 19 (27.1) | 51 (72.9) | 71 | 1.2, (0.64–2.1), 0.6 | 0.94, (0.5–1.8), 0.86 |
|
| |||||
| Nondiabetic | 64 (23.3) | 211 (76.7) | 275 | Reference | |
| Diabetic | 67 (58.3) | 5 (41.7) | 12 |
|
|